Germany · Delayed Price · Currency is EUR Ventripoint Diagnostics Statistics
Total Valuation
FRA:5V7 has a market cap or net worth of EUR 9.33 million. The enterprise value is 10.74 million.
| Market Cap | 9.33M |
| Enterprise Value | 10.74M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 167.89M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.19% |
| Shares Change (QoQ) | +2.17% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | n/a |
| Float | 167.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.80 |
| PB Ratio | -3.27 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.32 |
| EV / Sales | 99.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.39 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -423.71% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 82.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -51,078 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.40% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 47.05 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:5V7 had revenue of EUR 107,463 and -2.48 million in losses. Loss per share was -0.02.
| Revenue | 107,463 |
| Gross Profit | 107,463 |
| Operating Income | -2.27M |
| Pretax Income | -2.54M |
| Net Income | -2.48M |
| EBITDA | -2.27M |
| EBIT | -2.27M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 41,806 in cash and 1.44 million in debt, giving a net cash position of -1.40 million.
| Cash & Cash Equivalents | 41,806 |
| Total Debt | 1.44M |
| Net Cash | -1.40M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -2.85M |
| Book Value Per Share | -0.02 |
| Working Capital | -2.85M |
Cash Flow
| Operating Cash Flow | -1.03M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -2,113.82% |
| Pretax Margin | -2,359.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:5V7 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.19% |
| Shareholder Yield | -4.19% |
| Earnings Yield | -26.63% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:5V7 has an Altman Z-Score of -272.34 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -272.34 |
| Piotroski F-Score | 4 |